AR and prostate cancer: The above results indicate that the presence of DHT can significantly impact enzalutamide resistance in 22RV1 cells and support the notion that YIV-818A, RA-V, and RA-VII effectively inhibit AR and AR-V (AR splice variants) activity in prostate cancer cells.